throbber
CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`
`
`APPLICATION NUMBER:
`
`205552Orig2s000
`
`PROPRIETARY NAME REVIEW(S)
`
`
`
`
`
`

`

`
`
`Department of Health and Human Services
`Public Health Service
`Food and Drug Administration
`Center for Drug Evaluation and Research
`Office of Surveillance and Epidemiology
`Office of Medication Error Prevention and Risk Management
`
`Proprietary Name Review
`
`Date:
`
`
`
`August 15, 2013
`
`Kevin Wright, PharmD
`Division of Medication Error Prevention and Analysis
`Yelena Maslov, PharmD
`Division of Medication Error Prevention and Analysis
`
`Carol Holquist, RPh
`Division of Medication Error Prevention and Analysis
`Imbruvica (Ibrutinib) Capsules
`140 mg
`NDA 205552
`Pharmacyclics, Inc.
`2013-1060
`
`Reviewer:
`
`Team Leader:
`
`
`Division Director:
`
`Drug Name and Strength:
`
`Application Type/Number:
`Applicant/Sponsor:
`OSE RCM #:
`
`*** This document contains proprietary and confidential information that should not be
`released to the public.***
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 3357988
`
`

`

`
`
`CONTENTS
`
`1
`
`INTRODUCTION................................................................................................................... 1
`1.1
`Product Information ....................................................................................................... 1
`2 RESULTS................................................................................................................................ 2
`2.1
`Promotional Assessment ................................................................................................ 2
`2.2
`Safety Assessment.......................................................................................................... 2
`3 CONCLUSIONS ..................................................................................................................... 4
`3.1
`Comments to the Applicant............................................................................................ 4
`4 REFERENCES........................................................................................................................ 5
`APPENDICES................................................................................................................................. 8
`
`
`
`
`
`
`Reference ID: 3357988
`
`

`

`1
`
`INTRODUCTION
`
`This review evaluates the proposed proprietary name, Imbruvica, from a safety and
`promotional perspective. The sources and methods used to evaluate the proposed name
`are outlined in the reference section and Appendix A respectively.
`
`1.1
`
`PRODUCT INFORMATION
`
`The following product information is provided in the July 12, 2013 proprietary name
`submission.
`
`Intended pronunciation: Im-broo-vik-O
`
`is a Bruton tyrosine kinase inhibitor indicated for the treatment
`Indication of Use:
`of mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic
`lymphoma in patients who have receivedat least one prior therapy.
`
`Route of Administration: Oral
`
`Dosage Form: Capsule
`
`Strength: 140 mg
`
`Dose and Frequency:
`
`o Mantel cell lymphoma: 560 mgorally daily
`
`o Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma:
`420 mgorally daily
`
`o Dose Adjustment
`
`Chronic Lymphocytic
`Mantle cell lymphoma
`Toxicity
`
`Occurrence Modification after Recovery|Leukemia/Small Lymphocytic
`Lymphomaafter Recove
`
`Second
`Restart 420 mg dail
`
` First Restart at 560 mg daily Restart at 420 mg daily
`
`Restart at 280 mg dail Restart at 280 mg dail
`
`
`
`Discontinue therap
`
`Restart 140 mgdail
`
`How Supplied: 90 and 120 countbottles
`
`Storage: store between 20° to 25°C(68° to 77°F); excursions permitted between
`15° to 30° C (59° to 86°F)
`
`Container and Closure System: High density polyethylene (HDPE) bottles of 90
`and 120 capsules
`
`Reference ID: 3357988
`
`

`

`
`
`2 RESULTS
`The following sections provide information obtained and considered in the overall
`evaluation of the proposed proprietary name.
`
`2.1 PROMOTIONAL ASSESSMENT
`The Office of Prescription Drug Promotion (OPDP) determined the proposed name is
`acceptable from a promotional perspective. DMEPA and the Division of Hematology
`Products (DHP) concurred with the findings of OPDP’s promotional assessment of the
`proposed name.
`
`2.2
`SAFETY ASSESSMENT
`The following aspects were considered in the safety evaluation of the name.
`
`2.2.1 United States Adopted Names (USAN) SEARCH
`There is no USAN stem present in the proprietary name1.
`
`2.2.2 Components of the Proposed Proprietary Name
`The Applicant indicated in their submission that the proposed name, Imbruvica, has no
`listed derivation or intended meaning. This proprietary name is comprised of a single
`word that does not contain any components such as a modifier, route of administration,
`dosage form.
`
`2.2.3 FDA Name Simulation Studies
`Forty-seven practitioners participated in DMEPA’s prescription studies. The
`interpretations did not overlap with any currently marketed products nor did the
`misinterpretations sound or look similar to any currently marketed products or any
`products in the pipeline. In the written studies, 19 of 32 participants correctly interpreted
`the prescription. Common misinterpretations in the written study were substitution of
`‘ch’, for ‘im’ and ‘r’ for ‘c’. In the voice study 6 of 29 participants correctly interpreted
`the prescription. Common misinterpretations in the voice study include: ‘em’, for ‘im’
`and ‘pr’ for ‘br’. We have considered these variations in our look-alike and sound-alike
`searches and analysis (see Appendix B). Appendix C contains the results from the verbal
`and written prescription studies.
`
`2.2.4 Comments from Other Review Disciplines at Initial Review
`In response to the OSE, July 25, 2013 e-mail, the Division of Hematology Products
`(DHP) did not forward any comments or concerns relating to the proposed proprietary
`name at the initial phase of the review.
`
`
`1 USAN stem search conducted August 1, 2013.
`
`Reference ID: 3357988
`
`
`2
`
`

`

`2.2.5 Failure Mode and Effects Analysis ofSimilar Names
`
`Appendix B lists possible orthographic and phonetic misinterpretationsofthe letters
`appearing in the proposed proprietary name, Imbruvica. Table 1 lists the names with
`potential orthographic, phonetic, or spelling similarity to the proposed proprietary name,
`Imbruvica identified by the primary reviewer, the Expert Panel Discussion (EPD), and
`other review disciplines. Our analysis determined all 25 nameswill not posea risk for
`confusion as described in Appendices D through E.
`
`Table 1: Collective List of Potentially Similar Names (DMEPA, EPD, Other
`Disciplines, and External Name Study)
`
`Ambisome
`
`Emtriva
`
`FDA
`
`FDA
`
`Look Similar
`
`Brevicon
`
`Enfamil AR
`Lipil
`
`FDA
`
`FDA
`
`Eribulin
`
`FDA
`
`Estrovis
`
`FDA
`
`FDA
`EDA
`
`Imatinib
`Indinavir
`
`FDA
`FDA
`
`Embrex 600
`
`Enflurance
`
`Ibritumomab
`Tiuxetan
`
`Imipramine
`Infanrix
`
`FDA
`
`FDA
`
`FDA
`
`FDA
`EDA
`
`Iclusig
`Inderide
`40/25
`
`Influenza
`Virus
`Vaccine
`
`Intuniv
`
`Simbrinza (2)
`
`FDA
`
`Intermezzo
`
`FDA
`
`Introvale
`
`FDA
`
`FDA
`
`FDA
`
`Invocana
`
`Terbinex
`
`FDA
`
`FDA
`
`Irbesartan
`
`Uni-brom
`
`FDA
`
`FDA
`
`Look and SoundSimilar
`
`Imbruvica
`
`FDA
`
`2.2.6 Communication ofDMEPA’s Analysis at Midpoint ofReview
`
`DMEPA communicated our findings to the Division of Hematology Products (DHP) via
`e-mail on August 8, 2013. At that time we also requested additional information or
`concerns that could inform our review. Per e-mail correspondence from the Division of
`Hematology Products on August 15, 2013, they stated no additional concerns with the
`proposed proprietary name, Imbruvica.
`
`Reference ID: 3357988
`
`3
`
`

`

`
`
`3 CONCLUSIONS
`The proposed proprietary name is acceptable from both a promotional and safety
`perspective.
` If you have further questions or need clarifications, please contact Sue Kang, OSE
`project manager, at 301-796-4216.
`
`3.1
`COMMENTS TO THE APPLICANT
`We have completed our review of the proposed proprietary name, Imbruvica, and have
`concluded that this name is acceptable.
`The proposed proprietary name must be re-reviewed 90 days prior to approval of the
`NDA. The results are subject to change. If any of the proposed product characteristics as
`stated in your July 12, 2013 submission are altered, the name must be resubmitted for
`review.
`
`
`Reference ID: 3357988
`
`
`4
`
`

`

` REFERENCES
`
`
`
` 4
`
`1. Micromedex Integrated Index (http://csi.micromedex.com)
`Micromedex contains a variety of databases covering pharmacology, therapeutics,
`toxicology and diagnostics.
`
`2. Phonetic and Orthographic Computer Analysis (POCA)
`POCA is a database which was created for the Division of Medication Error
`Prevention and Analysis, FDA. As part of the name similarity assessment, proposed
`names are evaluated via a phonetic/orthographic algorithm. The proposed proprietary
`name is converted into its phonemic representation before it runs through the phonetic
`algorithm. Likewise, an orthographic algorithm exists which operates in a similar
`fashion.
`
`3. Drug Facts and Comparisons, online version, St. Louis, MO
`(http://factsandcomparisons.com)
`Drug Facts and Comparisons is a compendium organized by therapeutic course; it
`contains monographs on prescription and OTC drugs, with charts comparing similar
`products. This database also lists the orphan drugs.
`
`4. FDA Document Archiving, Reporting & Regulatory Tracking System [DARRTS]
`DARRTS is a government database used to organize Applicant and Sponsor
`submissions as well as to store and organize assignments, reviews, and
`communications from the review divisions.
`
`5. Division of Medication Errors Prevention and Analysis proprietary name
`consultation requests
`This is a list of proposed and pending names that is generated by the Division of
`Medication Error Prevention and Analysis from the Access database/tracking system.
`
`6. Drugs@FDA (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
`Drugs@FDA contains most of the drug products approved since 1939. The majority of
`labels, approval letters, reviews, and other information are available for drug products
`approved from 1998 to the present. Drugs@FDA contains official information about FDA
`approved brand name, generic drugs, therapeutic biological products, prescription and over-
`the-counter human drugs and discontinued drugs and “Chemical Type 6” approvals.
`7. U.S. Patent and Trademark Office (http://www.uspto.gov)
`USPTO provides information regarding patent and trademarks.
`
`8. Clinical Pharmacology Online (www.clinicalpharmacology-ip.com)
`Clinical Pharmacology contains full monographs for the most common drugs in
`clinical use, plus mini monographs covering investigational, less common,
`
`Reference ID: 3357988
`
`
`5
`
`

`

`
`
`combination, nutraceutical and nutritional products. It also provides a keyword search
`engine.
`
`9. Natural Medicines Comprehensive Databases (www.naturaldatabase.com)
`Natural Medicines contains up-to-date clinical data on the natural medicines, herbal
`medicines, and dietary supplements used in the western world.
`
`10. Access Medicine (www.accessmedicine.com)
`Access Medicine® from McGraw-Hill contains full-text information from
`approximately 60 titles; it includes tables and references. Among the titles are:
`Harrison’s Principles of Internal Medicine, Basic & Clinical Pharmacology, and
`Goodman and Gilman’s The Pharmacologic Basis of Therapeutics.
`
`11. USAN Stems (http://www.ama-assn.org/ama/pub/about-ama/our-people/coalitions-
`consortiums/united-states-adopted-names-council/naming-guidelines/approved-
`stems.shtml)
`USAN Stems List contains all the recognized USAN stems.
`
`12. Red Book (www.thomsonhc.com/home/dispatch)
`Red Book contains prices and product information for prescription, over-the-counter
`drugs, medical devices, and accessories.
`
`13. Lexi-Comp (www.lexi.com)
`Lexi-Comp is a web-based searchable version of the Drug Information Handbook.
`
`14. Medical Abbreviations (www.medilexicon.com)
`Medical Abbreviations dictionary contains commonly used medical abbreviations and
`their definitions.
`
`15. CVS/Pharmacy (www.CVS.com)
`This database contains commonly used over the counter products not usually
`identified in other databases.
`
`16. Walgreens (www.walgreens.com)
`This database contains commonly used over the counter products not usually
`identified in other databases.
`
`17. Rx List (www.rxlist.com)
`RxList is an online medical resource dedicated to offering detailed and current
`pharmaceutical information on brand and generic drugs.
`
`Reference ID: 3357988
`
`
`6
`
`

`

`
`
`18. Dogpile (www.dogpile.com)
`Dogpile is a Metasearch engine that searches multiple search engines including
`Google, Yahoo! and Bing, and returns the most relevant results to the search.
`
`19. Natural Standard (http://www.naturalstandard.com)
`Natural Standard is a resource that aggregates and synthesizes data on complementary
`and alternative medicine.
`
`Reference ID: 3357988
`
`
`7
`
`

`

`
`
`APPENDICES
`Appendix A
`FDA’s Proprietary Name Risk Assessment considers the promotional and safety aspects
`of a proposed proprietary name. The promotional review of the proposed name is
`conducted by OPDP. OPDP evaluates proposed proprietary names to determine if they
`are overly fanciful, so as to misleadingly imply unique effectiveness or composition, as
`well as to assess whether they contribute to overstatement of product efficacy,
`minimization of risk, broadening of product indications, or making of unsubstantiated
`superiority claims. OPDP provides their opinion to DMEPA for consideration in the
`overall acceptability of the proposed proprietary name.
`The safety assessment is conducted by DMEPA. DMEPA staff search a standard set of
`databases and information sources to identify names that are similar in pronunciation,
`spelling, and orthographically similar when scripted to the proposed proprietary name.
`Additionally, we consider inclusion of USAN stems or other characteristics that when
`incorporated into a proprietary name may cause or contribute to medication errors (i.e.,
`dosing interval, dosage form/route of administration, medical or product name
`abbreviations, names that include or suggest the composition of the drug product, etc.).
`DMEPA defines a medication error as any preventable event that may cause or lead to
`inappropriate medication use or patient harm while the medication is in the control of the
`health care professional, patient, or consumer. 2
`Following the preliminary screening of the proposed proprietary name, DMEPA gathers
`to discuss their professional opinions on the safety of the proposed proprietary name.
`This meeting is commonly referred to the Center for Drug Evaluation and Research
`(CDER) Expert Panel discussion. DMEPA also considers other aspects of the name that
`may be misleading from a safety perspective. DMEPA staff conducts a prescription
`simulation studies using FDA health care professionals. When provided, DMEPA
`considers external proprietary name studies conducted by or for the Applicant/Sponsor
`and incorporates the findings of these studies into the overall risk assessment.
`The DMEPA primary reviewer assigned to evaluate the proposed proprietary name is
`responsible for considering the collective findings, and provides an overall risk
`assessment of the proposed proprietary name. DMEPA bases the overall risk assessment
`on the findings of a Failure Mode and Effects Analysis (FMEA) of the proprietary name
`and misleading nature of the proposed proprietary name with a focus on the avoidance of
`medication errors.
`DMEPA uses the clinical expertise of its staff to anticipate the conditions of the clinical
`setting where the product is likely to be used based on the characteristics of the proposed
`product. DMEPA considers the product characteristics associated with the proposed
`product throughout the risk assessment because the product characteristics of the
`proposed may provide a context for communication of the drug name and ultimately
`determine the use of the product in the usual clinical practice setting.
`
`2 National Coordinating Council for Medication Error Reporting and Prevention.
`http://www nccmerp.org/aboutMedErrors html. Last accessed 10/11/2007.
`
`Reference ID: 3357988
`
`
`8
`
`

`

`
`
`Typical product characteristics considered when identifying drug names that could
`potentially be confused with the proposed proprietary name include, but are not limited
`to; established name of the proposed product, proposed indication of use, dosage form,
`route of administration, strength, unit of measure, dosage units, recommended dose,
`typical quantity or volume, frequency of administration, product packaging, storage
`conditions, patient population, and prescriber population. DMEPA considers how these
`product characteristics may or may not be present in communicating a product name
`throughout the medication use system. Because drug name confusion can occur at any
`point in the medication use process, DMEPA considers the potential for confusion
`throughout the entire U.S. medication use process, including drug procurement,
`prescribing and ordering, dispensing, administration, and monitoring the impact of the
`medication.3
`The DMEPA considers the spelling of the name, pronunciation of the name when spoken, and
`appearance of the name when scripted. DMEPA compares the proposed proprietary name
`with the proprietary and established name of existing and proposed drug products and names
`currently under review at the FDA. DMEPA compares the pronunciation of the proposed
`proprietary name with the pronunciation of other drug names because verbal communication
`of medication names is common in clinical settings. DMEPA examines the phonetic
`similarity using patterns of speech. If provided, DMEPA will consider the Sponsor’s intended
`pronunciation of the proprietary name. However, DMEPA also considers a variety of
`pronunciations that could occur in the English language because the Sponsor has little control
`over how the name will be spoken in clinical practice. The orthographic appearance of the
`proposed name is evaluated using a number of different handwriting samples. DMEPA
`applies expertise gained from root-cause analysis of postmarketing medication errors to
`identify sources of ambiguity within the name that could be introduced when scripting
`(e.g.,“T” may look like “F,” lower case ‘a’ looks like a lower case ‘u,’ etc). Additionally,
`other orthographic attributes that determine the overall appearance of the drug name when
`scripted (see Table 1 below for details).
`
`
`
`
`
`
`
`
`
`
`3 Institute of Medicine. Preventing Medication Errors. The National Academies Press: Washington DC.
`2006.
`
`Reference ID: 3357988
`
`
`9
`
`

`

`
`
`Table 1. Criteria Used to Identify Drug Names that Look- or Sound-Similar to a
`Proposed Proprietary Name.
`
`Considerations when Searching the Databases
`
`Attributes Examined to Identify
`Similar Drug Names
`
`Potential Effects
`
`Potential
`Causes of Drug
`Name
`Similarity
`
`Similar spelling
`
`
`Type of
`Similarity
`
`
`
`
`
`
`Look-
`alike
`
`Orthographic
`similarity
`
`Identical prefix
`Identical infix
`Identical suffix
`Length of the name
`Overlapping product
`characteristics
`
`• Names may appear similar
`in print or electronic media
`and lead to drug name
`confusion in printed or
`electronic communication
`• Names may look similar
`when scripted and lead to
`drug name confusion in
`written communication
`• Names may look similar
`when scripted, and lead to
`drug name confusion in
`written communication
`
`Similar spelling
`Length of the name/Similar
`shape
`Upstrokes
`Down strokes
`Cross-strokes
`Dotted letters
`Ambiguity introduced by
`scripting letters
`Overlapping product
`characteristics
`Identical prefix
`Identical infix
`Identical suffix
`Number of syllables
`Stresses
`Placement of vowel sounds
`Placement of consonant sounds
`Overlapping product
`characteristics
`Lastly, DMEPA considers the potential for the proposed proprietary name to
`inadvertently function as a source of error for reasons other than name confusion. Post-
`marketing experience has demonstrated that proprietary names (or components of the
`proprietary name) can be a source of error in a variety of ways. Consequently, DMEPA
`considers and evaluates these broader safety implications of the name throughout this
`assessment and the medication error staff provides additional comments related to the
`
`Sound-
`alike
`
`Phonetic
`similarity
`
`
`• Names may sound similar
`when pronounced and lead
`to drug name confusion in
`verbal communication
`
`Reference ID: 3357988
`
`
`10
`
`

`

`
`
`safety of the proposed proprietary name or product based on professional experience with
`medication errors.
`
`1. Database and Information Sources
`DMEPA searches the internet, several standard published drug product reference texts,
`and FDA databases to identify existing and proposed drug names that may sound-alike or
`look-alike to the proposed proprietary name. A standard description of the databases
`used in the searches is provided in the reference section of this review. To complement
`the process, the DMEPA uses a computerized method of identifying phonetic and
`orthographic similarity between medication names. The program, Phonetic and
`Orthographic Computer Analysis (POCA), uses complex algorithms to select a list of
`names from a database that have some similarity (phonetic, orthographic, or both) to the
`trademark being evaluated. Lastly, DMEPA reviews the USAN stem list to determine if
`any USAN stems are present within the proprietary name. The individual findings of
`multiple safety evaluators are pooled and presented to the CDER Expert Panel. DMEPA
`also evaluates if there are characteristics included in the composition that may render the
`name unacceptable from a safety perspective (abbreviation, dosing interval, etc.).
`
`2. Expert Panel Discussion
`DMEPA gathers gather CDER professional opinions on the safety of the proposed
`product and discussed the proposed proprietary name (Expert Panel Discussion). The
`Expert Panel is composed of Division of Medication Errors Prevention (DMEPA) staff
`and representatives from the Office of Prescription Drug Promotion (OPDP). We also
`consider input from other review disciplines (OND, ONDQA/OBP). The Expert Panel
`also discusses potential concerns regarding drug marketing and promotion related to the
`proposed names.
`The primary Safety Evaluator presents the pooled results of the database and information
`searches to the Expert Panel for consideration. Based on the clinical and professional
`experiences of the Expert Panel members, the Panel may recommend additional names,
`additional searches by the primary Safety Evaluator to supplement the pooled results, or
`general advice to consider when reviewing the proposed proprietary name.
`
`3. FDA Prescription Simulation Studies
`Three separate studies are conducted within the Centers of the FDA for the proposed
`proprietary name to determine the degree of confusion of the proposed proprietary name
`with marketed U.S. drug names (proprietary and established) due to similarity in visual
`appearance with handwritten prescriptions or verbal pronunciation of the drug name. The
`studies employ healthcare professionals (pharmacists, physicians, and nurses), and
`attempts to simulate the prescription ordering process. The primary Safety Evaluator
`uses the results to identify orthographic or phonetic vulnerability of the proposed name to
`be misinterpreted by healthcare practitioners.
`In order to evaluate the potential for misinterpretation of the proposed proprietary name
`in handwriting and verbal communication of the name, inpatient medication orders and/or
`outpatient prescriptions are written, each consisting of a combination of marketed and
`unapproved drug products, including the proposed name. These orders are optically
`
`Reference ID: 3357988
`
`
`11
`
`

`

`
`
`scanned and one prescription is delivered to a random sample of participating health
`professionals via e-mail. In addition, a verbal prescription is recorded on voice mail.
`The voice mail messages are then sent to a random sample of the participating health
`professionals for their interpretations and review. After receiving either the written or
`verbal prescription orders, the participants record their interpretations of the orders which
`are recorded electronically.
`
`4. Comments from Other Review Disciplines
`DMEPA requests the Office of New Drugs (OND) and/or Office of Generic Drugs
`(OGD), ONDQA or OBP for their comments or concerns with the proposed proprietary
`name, ask for any clinical issues that may impact the DMEPA review during the initial
`phase of the name review. Additionally, when applicable, at the same time DMEPA
`requests concurrence/non-concurrence with OPDP’s decision on the name. The primary
`Safety Evaluator addresses any comments or concerns in the safety evaluator’s
`assessment.
`
`The OND/OGD Regulatory Division is contacted a second time following our analysis of
`the proposed proprietary name. At this point, DMEPA conveys their decision to accept
`or reject the name. The OND or OGD Regulatory Division is requested to provide any
`further information that might inform DMEPA’s final decision on the proposed name.
`Additionally, other review disciplines opinions such as ONDQA or OBP may be
`considered depending on the proposed proprietary name.
`
`5. Safety Evaluator Risk Assessment of the Proposed Proprietary Name
`The primary Safety Evaluator applies his/her individual expertise gained from evaluating
`medication errors reported to FDA, considers all aspects of the name that may be
`misleading or confusing, conducts a Failure Mode and Effects Analysis, and provides an
`overall decision on acceptability dependent on their risk assessment of name confusion.
`Failure Mode and Effects Analysis (FMEA) is a systematic tool for evaluating a process
`and identifying where and how it might fail.4 When applying FMEA to assess the risk of
`a proposed proprietary name, DMEPA seeks to evaluate the potential for a proposed
`proprietary name to be confused with another drug name because of name confusion and,
`thereby, cause errors to occur in the medication use system. FMEA capitalizes on the
`predictable and preventable nature of medication errors associated with drug name
`confusion. FMEA allows the Agency to identify the potential for medication errors due
`to orthographically or phonetically similar drug names prior to approval, where actions to
`overcome these issues are easier and more effective than remedies available in the post-
`approval phase.
`In order to perform an FMEA of the proposed name, the primary Safety Evaluator must
`analyze the use of the product at all points in the medication use system. Because the
`proposed product is has not been marketed, the primary Safety Evaluator anticipates the
`use of the product in the usual practice settings by considering the clinical and product
`
`
`4 Institute for Healthcare Improvement (IHI). Failure Mode and Effects Analysis. Boston. IHI:2004.
`
`Reference ID: 3357988
`
`
`12
`
`

`

`
`
`characteristics listed in Section 1.2 of this review. The Safety Evaluator then analyzes
`the proposed proprietary name in the context of the usual practice setting and works to
`identify potential failure modes and the effects associated with the failure modes.
`In the initial stage of the Risk Assessment, the Safety Evaluator compares the proposed
`proprietary name to all of the names gathered from the above searches, Expert Panel
`Discussion, and prescription studies, external studies, and identifies potential failure
`modes by asking:
`“Is the proposed proprietary name convincingly similar to another drug name,
`which may cause practitioners to become confused at any point in the usual
`practice setting? And are there any components of the name that may function
`as a source of error beyond sound/look-alike?”
`An affirmative answer indicates a failure mode and represents a potential for the
`proposed proprietary name to be confused with another proprietary or established drug
`name because of look- or sound-alike similarity or because of some other component of
`the name. If the answer to the question is no, the Safety Evaluator is not convinced that
`the names posses similarity that would cause confusion at any point in the medication use
`system, thus the name is eliminated from further review.
`In the second stage of the Risk Assessment, the primary Safety Evaluator evaluates all
`potential failure modes to determine the likely effect of the drug name confusion, by
`asking:
`“Could the confusion of the drug names conceivably result in medication errors
`in the usual practice setting?”
`The answer to this question is a central component of the Safety Evaluator’s overall risk
`assessment of the proprietary name. If the Safety Evaluator determines through FMEA
`that the name similarity would not ultimately be a source of medication errors in the
`usual practice setting, the primary Safety Evaluator eliminates the name from further
`analysis. However, if the Safety Evaluator determines through FMEA that the name
`similarity could ultimately cause medication errors in the usual practice setting, the
`Safety Evaluator will then recommend the use of an alternate proprietary name.
`Moreover, DMEPA will object to the use of proposed proprietary name when the primary
`Safety Evaluator identifies one or more of the following conditions in the Overall Risk
`Assessment:
`a. OPDP finds the proposed proprietary name misleading from a promotional
`perspective, and the Review Division concurs with OPDP’s findings. The Federal
`Food, Drug, and Cosmetic Act provides that labeling or advertising can misbrand a
`product if misleading representations are made or suggested by statement, word,
`design, device, or any combination thereof, whether through a PROPRIETARY
`name or otherwise [21 U.S.C 321(n); See also 21 U.S.C. 352(a) & (n)].
`b. DMEPA identifies that the proposed proprietary name is misleading because of
`similarity in spelling or pronunciation to another proprietary or established name of a
`different drug or ingredient [CFR 201.10.(C)(5)].
`
`Reference ID: 3357988
`
`
`13
`
`

`

`
`
`c. FMEA identifies the potential for confusion between the proposed proprietary name
`and other proprietary or established drug name(s), and demonstrates that medication
`errors are likely to result from the drug name confusion under the conditions of usual
`clinical practice.
`d. The proposed proprietary name contains an USAN (United States Adopted Names)
`stem.
`e. DMEPA identifies a potential source of medication error within the proposed
`proprietary name. For example, the proprietary name may be misleading or,
`inadvertently, introduce ambiguity and confusion that leads to errors. Such errors
`may not necessarily involve confusion between the proposed drug and another drug
`product but involve a naming characteristic that when incorporated into a proprietary
`name, may be confusing, misleading, cause or contribute to medication errors.
`If DMEPA objects to a proposed proprietary name on the basis that drug name confusion
`could lead to medication errors, the primary Safety Evaluator uses the FMEA process to
`identify strategies to reduce the risk of medication errors. DMEPA generally
`recommends that the Sponsor select an alternative proprietary name and submit the
`alternate name to the Agency for review. However, in rare instances FMEA may identify
`plausible strategies that could reduce the risk of medication error of the currently
`proposed name. In that instance, DMEPA may be able to provide the Sponsor with
`recommendations that reduce or eliminate the potential for error and, thereby, would
`render the proposed name acceptable.
`In the event that DMEPA objects to the use of the proposed proprietary name, based upon
`the potential for confusion with another proposed (but not yet approved) proprietary
`name, DMEPA will provide a contingency objection based on the date of approval.
`Whichever product, the Agency approves first has the right to use the proprietary name,
`while DMEPA will recommend that the second product to reach approval seek an
`alternative name.
`The threshold set for objection to the proposed proprietary name may seem low to the
`Applicant/Sponsor. However, the safety concerns set forth in c

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket